Troy Ignelzi

Mr. Troy Ignelzi is the Chief Financial Officer of Karuna Therapeutics. He has more than 25 years of experience supporting companies in finance, business development, and operations. Mr. Ignelzi joined Karuna from scPharmaceuticals where he, in his role as Chief Financial Officer, helped oversee the company’s development from a privately-held clinical-stage organization to a publicly-traded biopharma preparing for commercial launch. Prior to scPharmaceuticals, Mr. Ignelzi served as Chief Financial Officer and a member of the executive leadership team at Juventas Therapeutics. He also previously served as Senior Vice President Operations and Business Development of Pharmalex GmbH, Vice President of Business Development at Esperion Therapeutics, and Vice President, Business Development & Strategic Planning at Insys Therapeutics. Mr. Ignelzi also has previous commercial experience, having launched and promoted CNS therapies while at Eli Lilly. Mr. Ignelzi currently serves as a member of the board of directors of Cincor Pharma and Vedanta Biosciences.

Mr. Ignelzi received his bachelor’s degree in Accounting from Ferris State University.
Speaking In
11:00 AM - 12:00 PM
Tuesday, June 6
The 33rd edition of EY’s Beyond Borders Biotechnology Report offers a chance to take stock of the…